RxDoctor Payments Data

James Crandell, MD

Cardiovascular Disease · Westlake, OHNPI 1396711610

Payments from drug & device makers

$44,051in general payments, 2019–2025

Across 139 payments — averaging $316.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$42K
  • Amgen$445
  • Johnson & Johnson$356
  • Esperion Therapeutics, Inc.$206
  • AstraZeneca$195
  • Abbott$145
  • plus $895 from 15 others

What the payments were for

  • Speaking & faculty fees$33,85577%
  • Travel & lodging$6,27414%
  • Food & beverage$3,7829%
  • Education$1390%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,051 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$192,994
Medicare patients
954
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban392$422,643
EntrestoSacubitril/Valsartan72$90,650
XareltoRivaroxaban85$88,755
JardianceEmpagliflozin60$59,801
VascepaIcosapent Ethyl51$31,492
Repatha SureclickEvolocumab11$13,338
Ezetimibe254$9,736
Icosapent Ethyl27$8,547
Dofetilide28$8,409
Rosuvastatin Calcium440$7,435
Metoprolol Succinate409$6,148
Atorvastatin Calcium343$3,377
Clonidine20$3,046
Flecainide Acetate39$3,028
Midodrine Hcl55$2,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$422,643392 claims
NovartisEntresto$38$90,65072 claims
Johnson & JohnsonXarelto$356$88,75585 claims
Boehringer IngelheimJardiance$121$59,80160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →